Edition:
India

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

102.80SEK
18 May 2018
Change (% chg)

0.20kr (+0.19%)
Prev Close
102.60kr
Open
102.00kr
Day's High
104.00kr
Day's Low
101.40kr
Volume
9,221
Avg. Vol
38,562
52-wk High
147.80kr
52-wk Low
91.30kr

Latest Key Developments (Source: Significant Developments)

Camurus Q1 Operating Loss SEK 46.4 Mln
Thursday, 3 May 2018 

May 3 (Reuters) - CAMURUS AB ::Q1 NET SALES MSEK 14.6 (17.2)..Q1 OPERATING RESULT MSEK -46.4 (-51.6).BOARD OF DIRECTORS HAS NOT CHANGED ITS OUTLOOK ON FUTURE DEVELOPMENTS.  Full Article

Camurus Q3 operating loss widens to SEK ‍67.1​ million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - CAMURUS AB :Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO.Q3 OPERATING LOSS SEK ‍-67.1​ MILLION VERSUS LOSS SEK 16.6 MILLION YEAR AGO.  Full Article

Camurus Q2 loss after tax narrows to SEK 20.6 million
Thursday, 14 Jul 2016 

Camurus AB : Q2 revenue 25.8 million Swedish crowns ($3 million) versus 22.7 million crowns year ago .Q2 loss after tax 20.6 million crowns versus loss 115.2 million crowns year ago.  Full Article

Camurus: Safety and local tolerability of CAM2029 in Phase 2 study was good
Tuesday, 12 Jul 2016 

Camurus AB : Announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors . In present study treatment with CAM2029 resulted in therapeutic blood-levels of octreotide over four weeks . Safety and local tolerability of CAM2029 was good and consistent with marketed reference product Sandostatin Lar .As next step looks forward to initiation of planned Phase 3 trials by collaborator Novartis.  Full Article

Camurus: Results from Phase 2 trial of CAM2032 in patients with prostate cancer
Tuesday, 21 Jun 2016 

Camurus AB : Announces results from a Phase 2 trial of CAM2032 in patients with prostate cancer . Positive results from a repeat-dose Phase 2 trial of two dose levels of leuprolide FluidCrystal injection depot (CAM2032 3.75 mg and 7.5 mg) and the active comparator, Eligard 7.5 mg, in patients with prostate cancer . Data from Phase 2 trial demonstrated comparable pharmacokinetic profiles for three treatments .Further development of CAM2032, including potential partnerships, is currently being evaluated.  Full Article

BRIEF-Camurus Q4 Operating Loss Widens To SEK ‍66.1​ Million

* Q4 NET SALES SEK ‍5.5​ MILLION VERSUS SEK 37.1 MILLION YEAR AGO